Change Agents Corporation. (CHGA) · Nov 5, 2026 · New debt
$250K bridge note — $250,000 borrowed; $325,000 due January 1, 2027
Change Agents’ new debt financing provides short-term cash but demands a steep near-term payoff, alongside 150,000 service shares and an interim CEO appointment.
Change Agents is trying to pivot from its former biotech identity into an AI-applications company, with recent launches aimed at small-business users and new distribution partnerships. The filing reads as a liquidity bridge, not operating progress. The company raised only $250,000 but must repay $325,000 on January 1, 2027—an unusually expensive 30% payoff premium in roughly two months. 〔0〕
| Term | November 4, 2026 | Comparison |
|---|---|---|
| Note principal (Debt terms) | $250,000 | |
| Repayment due (Debt terms) | $325,000 | January 1, 2027 |
| Prepayment amount (Debt terms) | $312,000 | December 1, 2026 |
| Common shares for services (Equity issuance) | 150,000 | $0 proceeds |
The financing adds to an already strained capital structure. Earlier 2026 filings show repeated short-term borrowing, costly repayment obligations, equity issuance for services and even a $20,000 advance from the chief strategy officer to make a loan payment, so this note appears to extend a recurring cash squeeze rather than fund a clearly identified growth milestone.
Management continuity is also unresolved. Luisa Ingargiola, previously chief strategy officer and formerly chief financial officer, was appointed principal executive officer only until a permanent CEO is found, with no additional compensation. 〔1〕 That keeps leadership functioning, but it does not remove the execution risk around the AI transition.
The equity issuance provides no cash relief. The company agreed to issue 150,000 shares to consultants for services already rendered, with no proceeds received. 〔2〕
Bottom line: This filing is mainly a costly stopgap financing, reinforced by fresh non-cash dilution and an unresolved CEO search. It weakens the company’s ability to fund its AI pivot on attractive terms and is materially worse than a routine capital raise would have been.
Note repayment or prepayment decision, January 1, 2027
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!